Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Dermatologic 2

Conditions

Melanoma 3Colitis 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hepatitis 1Graft vs Host Disease 1

Interventions

pembrolizumab 244Carboplatin 213Pemetrexed 179Cisplatin 133Paclitaxel 115Nivolumab 102Docetaxel 88osimertinib 84durvalumab 79Specimen Handling 56atezolizumab 55Gemcitabine 53Drug Therapy 53Magnetic Resonance Spectroscopy 50Radiosurgery 49Radiotherapy 48Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 35tislelizumab 31Cetuximab 30amivantamab 23Taxes 22Blood Specimen Collection 21Platinum Compounds 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × vedolizumab × 1 year × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT06646016 2025-12-26

EPIC

Therakos LLC

Phase 2 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡